2017 European Lung Cancer Conference

lung cancer

ELCC 2017: Prospective Study Shows Concordance of EGFR Mutation Detection Between ctDNA and Tumor Samples

Detection of EGFR mutations in circulating tumor (ct) DNA from plasma samples can be accomplished using the cobas platform, according to findings presented by Kumar et al at the 2017 European Lung Can...

lung cancer

ELCC 2017: Specific Immune Cell Profiles Potentially Identify Patients With Lung Cancer Responsive to Anti–PD-1 Immunotherapy

An investigation of immune cell subtypes in the tumor microenvironment of patients with lung adenocarcinoma and squamous cell carcinoma (SCC) identified an immune subgroup that associates with prolong...

lung cancer

ELCC 2017: Ensartinib Demonstrates CNS Activity in ALK-Positive NSCLC

Ensartinib demonstrated intracranial responses in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) and central nervous system (CNS) metastases, ac...

lung cancer

ELCC 2017: Development and Validation of Lung Toxicity Prediction Models Aids Effective Use of Radiotherapy in NSCLC

Validation using patient data of an outcome prediction model for the development of dyspnea subsequent to radiotherapy revealed that the prognostic factors in the model did not adequately predict for ...

lung cancer

ELCC 2017: Study Shows White Blood Cell–Boosting Drugs Safe During Small Cell Lung Cancer Chemoradiotherapy

A late-breaking subanalysis of the phase III CONVERT trial presented by Gomes et al at the 2017 European Lung Cancer Conference (ELCC) shows that white blood cell–boosting drugs are safe during ...

lung cancer

ELCC 2017: Some Patients With Lung Cancer Benefit From Immunotherapy Even After Disease Progression

Some patients with advanced lung cancer benefit from immunotherapy, even after the disease has progressed as evaluated by standard criteria, according to research presented by Artal-Cortes et al at th...

lung cancer

ELCC 2017: White Blood Cell Count May Predict Response to Lung Cancer Immunotherapy

White blood cell counts may predict whether patients with lung cancer will benefit from immunotherapy, according to research presented by Tiseo et al at the 2017 European Lung Cancer Conference (...

lung cancer

ELCC 2017: Osimertinib Improves Symptoms in Advanced Lung Cancer

Osimertinib (Tagrisso) improved cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented b...

lung cancer

ELCC 2017: Men May Need More Frequent Lung Cancer Screening Than Women

Men may need more frequent lung cancer screening than women, according to research to be presented by Koo et al at the 2017 European Lung Cancer Conference (ELCC). The U.S. Preventive Services Task F...

lung cancer
issues in oncology

ELCC 2017: Patients With Lung Cancer Treated With PD-1/PD-L1 Checkpoint Inhibitors May Experience Adverse Events After Influenza Vaccination

Patients with lung cancer treated with programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) checkpoint inhibitors may be at increased risk of adverse events after receiving the ...

Advertisement

Advertisement



Advertisement